^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB3823

    i
    Other names: TQB3823
    Company:
    Sino Biopharm
    Drug class:
    PARP1 inhibitor, PARP2 inhibitor
    Related drugs:
    6ms
    To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=39, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=78 --> 39 | Trial completion date: Apr 2024 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Jan 2024 --> Jul 2023; The sponsor voluntarily terminated the study
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    abiraterone acetate • prednisone • TQB3823
    3years
    [VIRTUAL] Characterization of TQB3823, a differentiated PARP inhibitor with anti-tumor activity in BRCA-deficiency cancer models (AACR 2021)
    The level of antitumor effects was superior to niraparib at the same dose in the same study. DNA trapping experiments revealed similar potency to olaparib indicative of low toxicity. We have identified a novel, potent and selective PARP inhibitor TQB3823, which inhibits the proliferation of BRCA mutant cells but spares the wild type cells. We have identified a novel, potent and selective PARP inhibitor TQB3823, which inhibits the proliferation of BRCA mutant cells but spares the wild type cells. In vivo study in a BRCA-deficiency tumor model confirms the high in vivo efficacy of this molecule. In conclusion, TQB3823 represents a promising differentiated clinical candidate for treating solid cancers with homology directed repair.
    Preclinical • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Zejula (niraparib) • TQB3823